ClinicalTrials.gg
Active, not recruitingNCT06565650Updated Dec 17, 2024

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

A Phase 4 interventional study of Miebo and Saline in Dry Eye, sponsored by Bausch & Lomb Incorporated. Active, not recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes — 1 open to participants now, 2 under way, none of them phase 3. perfluorohexyloctane · Dry Eye Syndromes.

Enrollment
7th of 13
216 · median 216
Started
2024
with 2 others
Phase 4
7 of 13
1 open now
Registered
8th of 13
by date
Lead sponsor
9 of 13
Bausch & Lomb Incorporated

Among the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, this one is the 7th largest by enrollment, is one of 3 that started in 2024, is one of 7 in phase 4, and was the 8th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About perfluorohexyloctane

perfluorohexyloctane: first FDA approval 2023 (MIEBO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, or all of them as a file.
02

Study summary

A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be at least 18 years of age at the time of consent.
  2. Have a self-reported history of DED in both eyes (OU) for at least 6 months prior to Visit 1 (Screening/Baseline)
  3. Have a total corneal fluorescein staining score (tCFS) score >2 in both eyes
  4. Have an Ocular Surface Disease Index (OSDI) score >17
  5. Have a baseline ECD ≥1750 cells/mm2 in each eye
  6. Provide written
  7. Be able and willing to follow instructions, including participation in all trial assessments and visits
  8. If a contact lens wearer, be willing to discontinue contact lens use during and for 30 minutes following instillation of drug and during study visits

Exclusion criteria

Exclusion Criteria:

  1. Be at least 18 years of age at the time of consent.
  2. Have a self-reported history of DED in both eyes (OU) for at least 6 months prior to Visit 1 (Screening/Baseline)
  3. Have a total corneal fluorescein staining score (tCFS) score >2 in both eyes
  4. Have an Ocular Surface Disease Index (OSDI) score >17
  5. Have a baseline ECD ≥1750 cells/mm2 in each eye
  6. Provide written
  7. Be able and willing to follow instructions, including participation in all trial assessments and visits
  8. If a contact lens wearer, be willing to discontinue contact lens use during and for 30 minutes following instillation of drug and during study visits
  9. Have any ocular surface slit lamp findings and/or in the opinion of the Investigator have any findings that may interfere with trial parameters in either eye
  10. Have an ocular or periocular in either eye
  11. Have a history of herpetic keratitis in either eye
  12. Have any planned ocular and/or lid surgeries in either eye during the course of the study
  13. Have a known allergy and/or sensitivity to the IP
  14. Have a history of ocular laser surgery in either eye within 3 months (90 days) prior to Visit 1 (Screening/Baseline)
  15. Have a history of incisional ocular surgery or severe trauma in either eye within 3 months (90 days) prior to Visit 1 (Screening/Baseline)
  16. Have high contrast best-corrected visual acuity equal to or worse than logMAR +0.7 (Snellen equivalent score of 20/100 or worse) as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) scale in either eye, obtained under bright room lighting
  17. Be a woman who is pregnant, nursing or planning a pregnancy during the course of the study
  18. Be a woman of who is unwilling to submit to a urine pregnancy test. Non-childbearing potential is defined as a woman who is permanently sterilized (eg, has had a hysterectomy or bilateral tubal ligation or bilateral oophorectomy) or is (without menses for 12 consecutive months).
  19. Be a woman of childbearing potential who is not using an acceptable method of . Acceptable methods of contraception include hormonal - oral, implantable, injectable, or transdermal - contraceptives; mechanical contraception - spermicide in conjunction with a barrier such as a diaphragm or condom; intrauterine device; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, the subject must agree to use adequate birth control as defined above for the remainder of the study if she becomes sexually active during the trial.
  20. Be currently enrolled in an investigational drug or device trial or plan to enroll during the course of the study
  21. Have a condition or be in a situation that the Investigator believes may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Miebo

    100% perfluorohexyloctane 4 times daily (QID)

    Drug: Miebo

  • Placebo comparator
    Saline solution

    (0.6% sodium chloride solution) 4 times daily (QID)

    Drug: Saline

Interventions

  • DrugMiebo

    100% perfluorohexyloctane

  • DrugSaline

    0.6% sodium chloride solution

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in ECD

    Mean change from baseline in ECD in the study eye at the Month 3 and Month 12 Visits

    Time frame: Assessed at Month 3 and Month 12 Visits

07

Study locations

12 sites
  • Site 101
    Glendale, California 91204, United States
  • Site 112
    Murrieta, California 92562, United States
  • Site 102
    Newport Beach, California 92663, United States
  • Site 109
    Rancho Cordova, California 95670, United States
  • Site 106
    Torrance, California 90505, United States
  • Site 113
    Delray Beach, Florida 33484, United States
  • Site 107
    Morrow, Georgia 30260, United States
  • Site 105
    Carmel, Indiana 46290, United States
  • Site 110
    Kansas City, Missouri 64111, United States
  • Site 104
    Saint Louis, Missouri 63131, United States
  • Site 108
    Asheville, North Carolina 28803, United States
  • Site 103
    Memphis, Tennessee 38119, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Nov 2025, 16 months after the start.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's planned 16 months is above that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 22, 2024
StartActual
Jul 31, 2024
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06565650
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Jul 31, 2024
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Dec 17, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perfluorohexyloctane

Start the discussion